TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00342108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cross-modal sensory stimulation
Description: comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cross-modal sensory stimulation
Description: comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
Study: NCT00528593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
Study: NCT03554564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICE/Fitbit
Description: During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)

Intervention type: OTHER
Group type: OTHER
Intervention: Daily self-reported exercise adherence
Description: During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
Study: NCT00746057

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DNA chip
Description: One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
Study: NCT01492335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Report
Description: Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
Study: NCT01052701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin plus Abacavir (ABC)
Description: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours
Study: NCT01174719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: volume replacement
Description: Hydroxyethylstarch up to 50mL/kg/24 hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humanalbumin 5%
Description: Humanalbumin 5% up to 50 mL/kg/24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: volume replacement
Description: up 10 50mL/kg/24 hours
Study: NCT02827929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
Study: NCT01328067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exablate 2100
Description: MRgFUS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myomectomy
Description: Non-Hysteroscopic Myomectomy
Study: NCT04571567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
Study: NCT02207088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet
Study: NCT01723319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBLPADD coil deep TMS
Description: 20 daily deep TMS treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: inactive treatment
Study: NCT02314819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fruquintinib
Description: fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Study: NCT03418818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAZA
Description: 18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole
Description: Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
Study: NCT00580307

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Septoplasty
Description: Surgical straightening of nasal septum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septoplasty and endoscopic contact point correction
Description: Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
Study: NCT04529018

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: [18F]CETO
Description: \[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: [18F]CETO
Description: \[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
Study: NCT00734539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: 6mg/kg IV/PO twice weekly for a total of up to 12-13 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
Study: NCT02270294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai traditional massage
Description: Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No massage
Description: The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
Study: NCT00953056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
Study: NCT01842217

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FES-PET

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FES-PET
Study: NCT01598506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
Study: NCT01415414

Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
Study: NCT00483977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: oral for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-000592379
Description: PF-00592379: oral, 30 mg, once a day for 2 weeks
Study: NCT03417154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Cyclophosphamide (CTX) Daily
Description: Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Cyclophosphamide (CTX) Every 7 Days
Description: Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
Study: NCT02387502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation- Macintosh laryngoscope
Description: Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation- MacCoy laryngoscope
Description: In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation- Airtraq laryngoscope
Description: In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
Study: NCT01885598

Intervention type: DRUG
Intervention: Apixaban
Study: NCT02864459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscular ultrasound
Description: Muscular ultrasound is done before extubation
Study: NCT02780752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hymecromone
Description: Oral Hymecromone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hymecromone
Description: Oral Hymecromone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hymecromone
Description: Oral Hymecromone
Study: NCT00995800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate / Formoterol fumarate
Description: 2 dose strength vs. placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate / Formoterol fumarate
Description: 2 dose strength vs. placebo
Study: NCT02611583

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation
Study: NCT01956838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: umami
Description: intraduodenal infusion of umami tastant

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: umami
Description: intraduodenal infusion of umami tastant

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bitter
Description: intraduodenal infusion of bitter tastant

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bitter
Description: intraduodenal infusion of bitter tastant

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sweet
Description: intraduodenal infusion of sweet tastant

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sweet
Description: intraduodenal infusion of sweet tastant
Study: NCT01684293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy-based cognitive rehabilitation
Description: Occupational therapy-based cognitive rehabilitation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation/games
Description: Psychoeducation/games
Study: NCT01647347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supra- and subgingival rinsing with 10% PVP-iodine
Description: rinsing prior to and during subgingival ultrasonic debridement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study: NCT00088764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training
Description: 8 sessions of pain and stress coping skills training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Description: 4 sessions of writing about stress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis education
Description: 8 sessions of learning about rheumatoid arthritis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health behavior writing
Description: 4 sessions of writing about various health behaviors
Study: NCT02902861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ( for Methotrexate)
Description: NaCl-Solution manufactured to mimic Methotrexate
Study: NCT01563809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH+LH
Description: 75 IU of LH will be given from stimulation day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH+LH
Description: 75 IU of LH will be given from stimulation day 1
Study: NCT02087696

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
Study: NCT02284243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Study: NCT00976560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
Study: NCT01227993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Study: NCT00889720

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
Study: NCT00175396

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Androgen suppression, radiotherapy
Description: Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Androgen suppression, radiotherapy, iodine 125 brachytherapy
Description: Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
Study: NCT00555516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EW02
Description: 1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EW02
Description: 1. Name: EW02~2. Dosage form: capsule.~3. Dose(s): 350mg per capsule, 2 capsule tid.~4. Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3.
Study: NCT01470118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alcaftadine 0.25% ophthalmic solution
Description: One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine 0.2% ophthalmic solution
Description: One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Description: One drop of placebo instilled in each eye at Day 0 and Day 14.
Study: NCT01339052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT01009216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: Doses will be administered daily for 5 days.
Study: NCT01663103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: 12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
Study: NCT00235365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meta-cognitive therapy
Description: Meta-cognitive therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waiting list
Description: waiting list control
Study: NCT02124993

Intervention type: OTHER
Intervention: Questionnaire
Description: Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
Study: NCT00363480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone 50/250 mcg
Description: Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 mcg
Description: This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS™ powder inhalers
Description: Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
Study: NCT04885777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Initially, a nasopharyngeal swab was performed on each group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, one ml of a solution containing 20 mg/ml of lidocaine, was applied to each nostril of the participants in the Lidocaine group. Thus, a total of 40 mg of lidocaine, 20 mg for each nostril, was given to the individuals of the Lidocaine group. The second samples were collected after waiting 5 minutes following the administration of the solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initially, a nasopharyngeal swab was performed on placebo group without any intervention. Investigators waited at least one hour for the second sample collection. If the participant was still in pain or felt discomfort due to the first sampling, the waiting time has been extended.~At the second stage, the Placebo group received only a total of 2 ml of 0.9% NaCl (one ml for each nostril). The second samples were collected after waiting 5 minutes following the administration of the solution.
Study: NCT00675610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication training
Description: providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
Study: NCT03557060

Intervention type: DRUG
Intervention: Nucala
Description: NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
Study: NCT02321176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trans-resveratrol
Description: patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient